CD274 and neoplasm: To overcome limitations associated with anti-PD-1/PD-L1 antibodies-such as low tumor accumulation and immunogenicity, another group developed nanoparticles via self-assembly containing Ce6, R848, and the PD-L1 inhibitor JQ1 (termed CRJ NPs).